GlassScriptPhysician profile
Andrew S Gardner
NPI 1336239896
$6,637.05
in general payments reported to CMS, 2019-2025
27 companies · $586 in 2025
The $586 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $551 · 2021: $977 · 2022: $1,223 · 2023: $1,155 · 2024: $794 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,477 · Education: $58.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,477.35 |
| Education | $58.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,443.92 | 2019-2023 | |
| Myovant Sciences INC. | $758.01 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $701.90 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $576.84 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $344.34 | 2023-2024 | |
| Evofem Biosciences, INC. | $308.99 | 2021-2025 | Phexxi, Solosec, Phexx |
| Alydia Health | $279.25 | 2021 | |
| Amag Pharmaceuticals, INC. | $274.02 | 2019-2020 | |
| Therapeuticsmd, INC. | $266.64 | 2019-2021 | |
| Lupin INC. | $247.39 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $205.36 | 2022-2023 | |
| Millicent US INC | $148.15 | 2019-2025 | Intrarosa, Femring |
| Hologic Sales and Service, LLC | $147.99 | 2019-2024 | Aptima |
| Coopersurgical, INC. | $145.14 | 2022-2023 | Paragard T 380a |
| Agile Therapeutics, INC. | $143.14 | 2021-2023 | Twirla |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $118.46 | 2019-2023 | Balcoltra |
| Exeltis, USA INC. | $105.31 | 2019-2022 | |
| Shield Therapeutics INC | $99.86 | 2023-2025 | Accrufer |
| Biogen, INC. | $83.52 | 2025 | Zurzuvae |
| Scynexis, INC. | $51.98 | 2022 | |
| Sage Therapeutics, LLC | $48.55 | 2019-2020 | |
| Mycovia Pharmaceuticals, INC. | $31.29 | 2024 | Vivjoa |
| Bayer Healthcare Pharmaceuticals INC. | $23.95 | 2019 | |
| Allergan, INC. | $22.49 | 2020 | |
| Merck Sharp & Dohme LLC | $20.50 | 2021 | |
| Covidien LP | $20.06 | 2019 | |
| Vertical Pharmaceuticals, LLC | $20.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.